Athersys, Inc. Announces Grant to Support Clinical Advancement of Its MultiStem® Regenerative Medicine Program for Heart Attack Patients
8/6/2013 9:59:40 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CLEVELAND, Aug. 6, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it has received a SBIR Fast Track grant from the National Heart, Lung, and Blood Institute, which will support a Phase 2 clinical study evaluating the administration of MultiStem® therapy to patients who have suffered a heart attack, or acute myocardial infarction (AMI). The grant is expected to provide up to $2.8 million in support over the course of the study in connection with study progress and milestone achievement.
Help employers find you! Check out all the jobs and post your resume.
comments powered by